<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247349</url>
  </required_header>
  <id_info>
    <org_study_id>CA001-030</org_study_id>
    <secondary_id>2014-002372-89</secondary_id>
    <nct_id>NCT02247349</nct_id>
  </id_info>
  <brief_title>BMS-986012 in Relapsed/Refractory SCLC</brief_title>
  <official_title>A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, pharmacokinetics,
      immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in
      combination with nivolumab in patients with relapsed/refractory SCLC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 30, 2014</start_date>
  <completion_date type="Anticipated">October 17, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by frequency of worst grade of adverse events (AEs), worst grade of serious adverse events (SAEs), incidence of adverse events leading to discontinuations, and deaths</measure>
    <time_frame>Weekly for 1st and 2nd 21-day cycles, then once every 3 weeks during study treatment, at end of treatment and every 30 days during clinical follow-up until resolution of adverse events or 100 days after the last dose of study medication (Approx 3 years)</time_frame>
    <description>Safety as measured by frequency of worst grade of adverse events (AEs), worst grade of serious adverse events (SAEs), incidence of adverse events leading to discontinuations, and deaths graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), as appropriate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum concentration at the end of a dosing interval (Ctau) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time t (AUC(0-t)) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing interval (AUC(TAU)) for BMS-986012 (anti-fucosyl-GM1) in combination with Nivolumab</measure>
    <time_frame>At multiple timepoints during first 4 cycles then every 4th cycle, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Best overall response (BOR): defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Objective Response Rate (ORR): defined as the total number of subjects whose best overall response (BOR) is either a complete response (CR) or partial response (PR) divided by the total number of subjects in the population of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Duration of Response: defined as the time between the date of first response and the subsequent date of objectively documented disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Progression Free Survival (PFS): defined as the time from the first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival Rate (PFSR) at week &quot;t&quot;; for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Progression Free Survival Rate (PFSR) at week &quot;t&quot;: defined as the proportion of subjects who remain progression free and surviving at &quot;t&quot; weeks (t=12, 24, 36, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Overall Survival (OS): defined as the time between the date of first dose of study medication and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate (OSR) at month &quot;t&quot; for BMS-986012 (anti-fucosyl-GM1)</measure>
    <time_frame>Approximately every 6 weeks until disease progression or every 3-4 months for subjects with a confirmed response (Approx duration of study 3 years)</time_frame>
    <description>Overall Survival Rate (OSR) at month &quot;t&quot;: defined as the proportion of subjects surviving at &quot;t&quot; months (eg, t=6, 12, 24 months, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up</measure>
    <time_frame>Every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of specific anti-drug antibodies (ADA) to BMS-986012 in combination with Nivolumab every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up</measure>
    <time_frame>Every 3 weeks for first 3 cycles then every 4 cycles, at end of treatment and during clinical follow-up (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the QTcF following administration of BMS-986012 at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment</measure>
    <time_frame>At multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the QTcF following administration of BMS-986012 in combination with Nivolumab at multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment</measure>
    <time_frame>At multiple timepoints during first cycle, then Day 1 of subsequent cycles and at end of treatment (Approx duration of study 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Monotherapy) Dose -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Monotherapy)- Cohort A (Refractory)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Monotherapy) Cohort B (Refractory)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Monotherapy) Cohort C (Sensitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Monotherapy) Cohort D (Sensitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Combination) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation (Combination) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Combination)- (Refractory and Sensitive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986012 (anti-fucosyl-GM1)</intervention_name>
    <arm_group_label>Dose Escalation (Monotherapy) Dose -1</arm_group_label>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 1</arm_group_label>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 2</arm_group_label>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 3</arm_group_label>
    <arm_group_label>Dose Escalation (Monotherapy) Dose 4</arm_group_label>
    <arm_group_label>Dose Expansion (Monotherapy)- Cohort A (Refractory)</arm_group_label>
    <arm_group_label>Dose Expansion (Monotherapy) Cohort B (Refractory)</arm_group_label>
    <arm_group_label>Dose Expansion (Monotherapy) Cohort C (Sensitive)</arm_group_label>
    <arm_group_label>Dose Expansion (Monotherapy) Cohort D (Sensitive)</arm_group_label>
    <arm_group_label>Dose Escalation (Combination) Dose 1</arm_group_label>
    <arm_group_label>Dose Escalation (Combination) Dose 2</arm_group_label>
    <arm_group_label>Dose Expansion (Combination)- (Refractory and Sensitive)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Dose Escalation (Combination) Dose 1</arm_group_label>
    <arm_group_label>Dose Escalation (Combination) Dose 2</arm_group_label>
    <arm_group_label>Dose Expansion (Combination)- (Refractory and Sensitive)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histological or cytological confirmed small cell lung cancer (SCLC)

          -  Performance Status 0-1

          -  Adequate organ function

          -  Measurable disease

        Exclusion Criteria:

          -  Known or suspected brain metastasis

          -  Small cell cancer not lung in origin

          -  Significant or acute medical illness

          -  Uncontrolled or significant cardiac disease

          -  Infection

          -  â‰¥ Grade 2 peripheral neuropathy

          -  Concomitant malignancies

          -  HIV related disease or known or suspected HIV+

          -  Hepatitis B or C infection

          -  ECG abnormalities as defined by the protocol

          -  Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related
             compounds, including fucosyl-GM1 vaccine and Nivolumab

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

